Pre-Submission Communication Issues May Hurt Regeneron’s Arcalyst In Gout
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warned in pre-submission meetings that the company’s safety database may not be adequate and those questions remain as the application goes to the Arthritis Advisory Committee.
You may also be interested in...
Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,” as well as chemistry, manufacturing and controls information.
Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.